Focus on access helps EQRx find receptive audience in the UK

Drug price disruptor EQRx has signed a memorandum of understanding (MoU) with the UK’s National Health Service, outlining plans for a long-term partnership to supply medicines.

The firm’s lead oncology programs, aumolertinib and sugemalimab, have been granted Innovation Passport designations by the UK regulatory authorities.

This new pathway provides a route to faster approval, rolling review and continuous benefit-risk assessment.